Special Issue "Cognitive Impairment and Depression"

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Social Cognitive and Affective Neuroscience".

Deadline for manuscript submissions: 25 August 2023 | Viewed by 1242

Special Issue Editors

1. School of Nursing and Midwifery, Edith Cowan University, Perth, WA, Australia
2. School of Nursing and Midwifery, Trinity College, Dublin, Ireland
Interests: large and small cerebral vessel disease; neurodegeneration; cognitive dysfunction; mood disorders; neurorehabilitation after stroke; biomarkers associated with cognition and stroke; life course development; behavioural health and health psychology; healthcare systems, innovations and clinical guidelines
Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
Interests: depression; cognitive impairments; Alzheimer's disease; dementia; focal dystonia; MRI; gray matter volume; micro-structure; functional connectivity; DTI

Special Issue Information

Dear Colleagues,

In the last two decades, there has been increasing amount of interest in the relationship between mood and emotional status influencing cognitive function. Available evidence supporting the association between mood disorders, e.g., depression, and cognitive impairment has been well documented in different disease groups and patient cohorts. Despite the historical evidence made between cognition and emotion in terms of brain localization and connectivity, disease-related studies have not always acknowledged this neuroscientific basis and connection.

This Special Issue of Brain Sciences aims to present evidence from healthy and disease groups, highlighting the association between cognitive impairment and depression in different cohorts to include healthy adults and patients across the life course in addition to age-related studies. Some key objectives will be to identify (1.) factors explaining the association between cognitive impairment and depression at clinical and molecular levels; (2.) variations in measurement and assessment of cognitive impairment and depression in patient cohort studies; (3.) address the association from the perspectives of severity, and types of cognitive impairment and depression; (4) the specific and common patterns associated with depression and cognitive impairment; (5) the mechanism of potential treatments or interventions for depression and cognitive impairment; and (6) whether depression is the risk fact for  transformation of cognitive impairment to dementia or AD.  

Prof. Dr. Claire Donnellan
Dr. Jinping Xu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cognitive impairment
  • cognitive dysfunction
  • mood disorders
  • depression
  • major depression disorders
  • bipolar disorders
  • emotion
  • cognition

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Antidepressant Activities of Synthesized Benzodiazepine Analogues in Mice
Brain Sci. 2023, 13(3), 523; https://doi.org/10.3390/brainsci13030523 - 21 Mar 2023
Viewed by 912
Depression is a serious psychological disorder which negatively affects human feelings and actions. The use of antidepressants is the therapy of choice while treating depression. However, such drugs are associated with severe side effects. There is a need for efficient and harmless drugs. [...] Read more.
Depression is a serious psychological disorder which negatively affects human feelings and actions. The use of antidepressants is the therapy of choice while treating depression. However, such drugs are associated with severe side effects. There is a need for efficient and harmless drugs. In this connection, the present study was designed to synthesize several substituted benzodiazepine derivatives and explore their antidepressant potentials in an animal model. The chalcone backbone was initially synthesized, which was then converted into several substituted benzodiazepine derivatives designated as 16. The synthesized compounds were identified using spectroscopic techniques. The experimental animals (mice) after acclimatation were subjected to forced swim test (FST) and tail suspension test (TST) after oral administration of the synthesized compounds to evaluate their antidepressant potentials. At the completion of the mentioned test, the animals were sacrificed to determine GABA level in their brain hippocampus. The chloro-substituent compound (2) significantly reduced the immobility time (80.81 ± 1.14 s; p < 0.001 at 1.25 mg/kg body weight and 75.68 ± 3.73 s with p < 0.001 at 2.5 mg/kg body weight dose), whereas nitro-substituent compound (5) reduced the immobility time to 118.95 ± 1.31 and 106.69 ± 3.62 s (p < 0.001), respectively, at the tested doses (FST). For control groups, the recorded immobility time recorded was 177.24 ± 1.82 s. The standard drug diazepam significantly reduced immobility time to 70.13 ± 4.12 s while imipramine reduced it to 65.45 ± 2.81 s (p < 0.001). Similarly, in the TST, the compound 2 reduced immobility time to 74.93 ± 1.14 s (p < 0.001) and 70.38 ± 1.43 s (p < 0.001), while compound 5 reduced it to 88.23 ± 1.89 s (p < 0.001) and 91.31 ± 1.73 s (p < 0.001) at the tested doses, respectively, as compared to the control group immobility time (166.13 ± 2.18 s). The compounds 1, 3, 4, and 6 showed weak antidepressant responses as compared to compounds 2 and 5. The compounds 2 and 5 also significantly enhanced the GABA level in the brain’s hippocampus of experimental animals, indicating the possible involvement of GABAergic mechanism in alleviating the depression which is evident from the significant increase in mRNA levels for the α subunit of the GABAA receptors in the prefrontal cortex of mice as well. From the results, it can be concluded that compound 2 and 5 could be used as alternative drugs of depression. However, further exploration in this connection is needed in other animal models in order to confirm the observed results in this study. Full article
(This article belongs to the Special Issue Cognitive Impairment and Depression)
Show Figures

Figure 1

Back to TopTop